49 results about "Echinococcoses" patented technology

The invention relates to a sheep echinococcosis classification model and classification method based on multi-source Raman spectrum domain migration of target related knowledge mining. The sheep echinococcosis classification model based on multi-source Raman spectrum domain migration of target related knowledge mining comprises a Raman spectrum data input module used for obtaining and inputting serum Raman spectrum data of healthy sheep and echinococcosis sick sheep; the MRKMTAR-MPAT module comprises an MRKM-TA R sub-module and an MPAT sub-module, and is used for deeply extracting target related knowledge in a multi-source domain and guiding adaptive reconstruction of a target domain; and the PGST module is used for realizing dynamic alignment of decision boundaries of the multi-source classifier by integrating pseudo labels and uncertain sensing information predicted by the multi-source classifier. According to the sheep echinococcosis classification model and classification method for multi-source Raman spectrum domain migration based on target related knowledge mining, the problem of knowledge degradation caused by multi-domain distribution offset in Raman spectrum medical data is solved.

The invention relates to the technical field of tapeworm identification, and provides a kit for identifying five target tapeworms by using specific primers and application of the kit. All mainstream genotypes of genes of Echinococcus granulosus, Echinococcus multilocularis, Taenia vesicula, Taenia multiceps and Taenia canis are compared, and a primer pair capable of universally detecting nucleic acids of five tapeworms is obtained by taking conserved regions of the genes as diagnostic targets. The rapid detection of the five pathogens is realized by combining with a digoxin-labeled nucleic acid lateral chromatography test paper. A product obtained by isothermal amplification is detected by a nucleic acid detection test strip and then is directly observed by eyes, and the result is interpreted within 15-20 minutes, so that the operation is simple and convenient. The method provided by the invention has wide application prospects in the aspects of large-scale screening and detection of whether dogs are infected with echinococcus granulosus, echinococcus multilocularis, taenia vesicula, taenia multiceps and tapestoma dogs or not in pasturing areas, especially in areas with epidemic echinococcosis, and evaluation of the insect expelling effect of the dogs fed with praziquantel on the tapeworms.

The invention discloses a primer pair, a kit and a method for detecting echinococcosis based on circulating free DNA, and relates to the field of molecular biological detection. According to the method, a sample to be detected is added into an RPA-CRISPR amplification detection system for synchronous isothermal amplification and CRISPR / Cas reaction, the sample to be detected is cfDNA extracted from blood of a patient, and the RPA-CRISPR amplification detection system comprises an RPA primer pair, crRNA, a Cas12a reporter probe, Cas12a protein, a buffer solution and nuclease-free water. Circulating free DNA of a patient is taken as a detection sample, a tissue sample of the patient does not need to be obtained, the patient cannot be wounded, implementation is easy, and the patient acceptability is high; the RPA-CRISPR amplification detection system constructed by the invention can simultaneously perform nucleic acid amplification and detection, so that the detection period is shortened, the cost is reduced, the operation process is simplified, a nucleic acid amplification product does not need to be uncovered and transferred, and the risk that a sample to be detected is polluted can be reduced.

The invention discloses application of lenvatinib (E7080) in treatment of alveolar echinococcosis, and belongs to the field of biomedicine. The technical problem to be solved by the invention is how to treat and / or prevent alveolar echinococcosis. It is found that lenvatinib (E7080) can cause falling of a head hook of an original head section of echinococcus multilocularis, shrinkage of a body section, damage to structures such as a suction cup and microvillus, and the in-vivo pathogenicity is remarkably reduced; the structure of the vesicles in the middle polyester period can be destroyed, so that the hair growth layers of the vesicles shrink and are separated from the cuticle. It is shown that lenvatinib (E7080) has a good killing effect on echinococcus multilocularis and can be used for preparing the medicine for treating the alveolar echinococcosis.

The invention belongs to the technical field of biological detection, and particularly discloses a pair of echinococcosis detection markers based on serum circulating miRNA and application of the echinococcosis detection markers, the detection markers are a combination of miR-192-5p and miR-122-5p, the abundance of the miR-192-5p and the miR-122-5p in the serum of an echinococcosis patient is remarkably reduced, the miR-192-5p and the miR-122-5p are in negative correlation with echinococcosis infection, and the threshold values are 0.35 and 0.04 respectively. During detection, the relative expression level (taking caenorhabditis elegans miR-39-3p as an external reference) of caenorhabditis elegans miR-39-3p in serum is determined through qPCR, and the positive and negative properties are judged according to a threshold value; the area under the ROC curve of the marker combination reaches 0.97, and a double-blind test shows that the positive rate and the negative rate of human and mouse serum detection are 100%. The method solves the problems of missed diagnosis and misdiagnosis in existing echinococcosis detection, can be used for preparing a detection kit, realizes accurate detection, curative effect evaluation and prognosis management of echinococcosis, and has extremely high clinical application value.

The application discloses a liver damage model caused by echinococcosis and a lesion tissue positioning method, which comprises an image acquisition module, a processor, a memory and a display which are connected with each other. On the basis of a three-dimensional liver ultrasonic image, after image gray processing, convolution operation is carried out, and the three-dimensional image is divided into two-dimensional images which are easy to process. Through feature extraction and data type merging, division of different liver tissue regions is realized, and whether liver echinococcosis is alive or not can be accurately judged, meanwhile, false points are eliminated, lesion tissue judgment efficiency is higher, precise positioning of lesion tissue can be realized, judgment can be realized without the help of professional knowledge of medical staff, treatment efficiency is high, and surgical risk is low.

The invention discloses an echinococcus granulosus PLGA-EgG1Y162 nano subunit vaccine and a preparation method thereof, and relates to the field of biomedical engineering and parasitic disease prevention and treatment. According to the method, echinococcus granulosus EgG1Y162 recombinant protein (the amino acid sequence is as shown in SEQ ID NO.1) is taken as an antigen core, and is stably coated in a polylactic acid-glycolic acid copolymer (PLGA) nano carrier through an innovative embedding process, so that the nano subunit vaccine in a brand new form is constructed. Compared with pure EgG1Y162 recombinant protein, the nanoparticles prepared by the preparation method disclosed by the invention not only have innovated components, but also obviously improve the slow release performance of drugs, and can realize precise enrichment and long-acting release of antigens. The invention fills up the blank of research on the echinococcus granulosus PLGA nano subunit vaccine, provides a novel technical scheme for prevention and treatment of echinococcosis, and has important application value and market prospect in the field of biological medicine.

The present invention provides an antigenic polypeptide, a nucleic acid encoding the antigenic polypeptide, an expression vector comprising the nucleic acid, a cell comprising the antigenic polypeptide, the nucleic acid, or the expression vector, and a vaccine for echinococcosis and a method for preparing the same. The antigenic polypeptide described herein can induce an immune response and induce the proliferation of specific B cells.

The application discloses a PSAP-3 protein fragment and application thereof in human echinococcosis. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. The application further discloses a recombinant protein or a mutation thereof, wherein the recombinant protein comprises an amino acid sequence as shown in SEQ ID NO:5, and the amino acid sequence of the mutation has at least 80% identity with the amino acid sequence of the recombinant protein. The immunoreaction rate of the PSAP-3 recombinant protein of the application is 100%, the echinococcosis can be effectively detected, the positive detection rate is 96%, the negative detection rate is 90%, and the positive patient that cannot be detected by Egr can be detected.

The present invention provides an antigenic polypeptide related to echinococcosis, a nucleic acid encoding the antigenic polypeptide and a vector containing the nucleic acid, and a cell containing the antigenic polypeptide or nucleic acid. At the same time, a echinococcosis vaccine is provided. This application uses the echinococcosis recombinant protein P29 as the research basis to screen and optimize peptide epitope molecules with immune effects, which is of great value in diagnosing echinococcosis, screening drugs for treating or preventing echinococcosis, and providing decision support for clinical treatment.

The invention relates to a molecular marker primer, a kit and a method for rapidly identifying an Echinococcus granulosus gene, and belongs to the technical field of biomolecular marker detection. The molecular marker primer for rapidly identifying the Echinococcus granulosus gene comprises a forward primer EG PrimerF, a reverse primer EG PrimerF, a reverse primer EG PrimerF, a reverse primer EG PrimerF, a reverse primer EG PrimerF, a reverse primer EG PrimerF and a reverse primer EG PrimerF, the sequence of the reverse primer EG Primer R is GAATGCTGC TGACTAACGAG, and the sequence of the reverse primer EG Primer R is GAATGCTGC TGACTAACGAG. According to the molecular marker primer, the kit and the method for rapidly identifying the Echinococcus granulosus gene, the target DNA is subjected to PCR amplification by utilizing the primer, a specific band near 480bp is detected through agarose gel electrophoresis, and the Echinococcus granulosus gene can be rapidly and accurately identified. Based on existing genome data and a traditional molecular biological technology, the problem that a traditional detection method is insufficient in specificity is solved, and an efficient scheme is provided for early diagnosis and large-scale screening of echinococcosis.

The invention discloses an application of a Serpin type serine protease inhibitor SPI-1-siRNA (small interfering Ribonucleic Acid) in treating two types of echinococcosis. The invention belongs to the technical field of biology, and particularly relates to application of a Serpin type serine protease inhibitor SPI-1-siRNA to treatment of two types of echinococcosis. The invention provides siRNA which can be used for preparing products for treating and preventing cystic echinococcosis and alveolar echinococcosis. And preparing a product for treating or / and preventing diseases caused by the infection of the cystic hydatid and the vesicular hydatid, and / or the infection of the cystic hydatid and the vesicular hydatid. The sequence of the siRNA is a double-stranded RNA consisting of two single-stranded RNAs as shown in SEQ ID No. 1 and SEQ ID No. 2 in a sequence table.

The invention discloses application of kaempferol in preparation of a medicine for treating echinococcosis, and relates to the technical field of biological medicines. The invention further discloses a medicine for treating echinococcosis. The medicine comprises kaempferol. The dosage form of the medicine is any pharmaceutically acceptable dosage form, and comprises, but not limited to, tablets, granules, capsules, pills, oral liquid, injections and lipidosome. The invention finds that the kaempferol has the effect of killing the protoscolex of the echinococcosis, can obviously inhibit the growth of the tissue of the echinococcosis, has no obvious cytotoxicity in effective concentration and no influence on liver and kidney functions, can be used as a safe and effective medicine for treating echinococcosis, and has a relatively great clinical application value.

The invention relates to a hepatic echinococcosis focus identification and classification method based on deep learning. The method comprises the following steps: when a focus exists in a to-be-detected liver ultrasonic image, generating focus detection state information of each focus in the to-be-detected liver ultrasonic image, and for any focus, when the pathological type of the focus is benign, performing coarse classification detection on the focus in a focus detection frame to generate coarse classification information of the focus; for any lesion, when the coarse classification information of the lesion is cystic hydatid type or vesicular hydatid type, determining that the lesion is a hepatic echinococcosis lesion, and performing hydatid subdivision category detection and lesion contour segmentation on the lesion to determine a corresponding hydatid subdivision category when the lesion belongs to the cystic hydatid type or vesicular hydatid type, and if the lesion belongs to the vesicular hydatid type or vesicular hydatid type, determining that the lesion belongs to the hepatic echinococcosis lesion. And a target contour of the lesion. According to the invention, the identification and classification of the hepatic echinococcosis can be effectively realized, and the precision and reliability of hepatic echinococcosis detection are improved.

The invention belongs to the field of molecular biology detection, specifically relates to detection of echinococcosis, and more specifically relates to detection of echinococcosis typing and / or prognosis. The composition provided by the invention has the advantages of higher detection sensitivity (up to 500 copies / mL), good specificity and more accurate detection, provides more sufficient and rapid diagnosis for clinicians, shortens the time of the clinicians for diagnosing the condition of a patient, and accelerates the implementation of treatment measures on the patient.

The application relates to the technical field of echinococcosis medicines, and is an application of a Toll-like receptor agonist Resiquimod in preparation of an echinococcosis treatment medicine. The application discloses, for the first time, the application of the Toll-like receptor agonist Resiquimod in preparation of the echinococcosis treatment medicine. The Toll-like receptor agonist Resiquimod can promote the fibrosis of the tissue around a lesion of a mouse infected with multilocular metacestode and further inhibit the growth of the multilocular metacestode, and reduce the lesion volume of the liver of the mouse infected with the multilocular metacestode, thereby providing a new way for echinococcosis treatment.

The present invention discloses the use of the fatty acid amide hydrolase inhibitor PF-3845 as a drug for the preparation of a drug for treating alveolar echinococcosis. The present invention finds that the fatty acid amide hydrolase inhibitor PF-3845 can destroy the head hook, sucker, microvilli and other structures of the protoscolecus of Echinococcus multilocularis, causing the protoscolecus to lyse and die, and can also destroy the structure of the vesicles in the tapeworm stage, causing the vesicles to collapse. This shows that the fatty acid amide hydrolase inhibitor PF-3845 has a good killing effect on Echinococcus multilocularis and can be used as an alternative to albendazole to treat echinococcosis, with good application prospects.

The invention relates to the technical field of molecular biology detection, in particular to a cattle and sheep universal type echinococcosis ELISA diagnostic kit and application thereof.The cattle and sheep universal type echinococcosis ELISA diagnostic kit comprises an SPG-HRP conjugate, the SPG-HRP conjugate is obtained by coupling SPG recombinant protein and horse radish peroxidase, the SPG recombinant protein comprises r2CSPG and r3CSPG, the amino acid sequence of the r2CSPG recombinant protein is shown as SEQ ID NO.1, the amino acid sequence of the r3CSPG recombinant protein is shown as SEQ ID NO.2, and the amino acid sequence of the r3CSPG recombinant protein is shown as SEQ ID NO.2. The amino acid sequence of the r3CSPG recombinant protein is as shown in SEQ ID NO. 2. The problem of how to apply the streptococcus protein G to early screening and early diagnosis of echinococcosis is solved.

The invention provides application of all-transretinoic acid in preparation of drugs for treating echinococcosis infection, and belongs to the technical field of biological drugs. The invention relates to an application of all-transretinoic acid in preparation of a medicine for treating echinococcosis infection or an application in preparation of a medicine for improving intestinal flora imbalance and / or immunosuppression microenvironment caused by echinococcosis infection. The all-transretinoic acid can obviously reduce the proportion of immunosuppressive cells MDSCs in the spleen of the host infected by the echinococcosis and reduce the abundance of lactobacillus in the intestinal flora of the host, so that the cyst weight is reduced, and the severity of the disease is improved. Therefore, development of drugs for targeting intestinal flora and host immunoregulation based on all-transretinoic acid provides technical support for efficient prevention and treatment of echinococcosis and other immune-related diseases, and social benefits are obvious.

The application discloses a VAT1L protein fragment and application thereof in human echinococcosis detection. The polypeptide comprises one or more of the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5. The application further discloses a recombinant protein or a mutation thereof, wherein the recombinant protein comprises an amino acid sequence shown in SEQ ID NO:6; the amino acid sequence of the mutation has at least 80% identity with the amino acid sequence of the recombinant protein and maintains the function of the recombinant protein. The immunoreaction rate of the VAT1L recombinant protein is 56%, the echinococcosis can be effectively detected, the positive detection rate is 82%, the negative detection rate is 84%, and the positive cases that cannot be detected by Egr can be detected.

The invention relates to the technical field of medicine preparation, in particular to a medicine composition for treating alveolar echinococcosis and application thereof, and the medicine composition comprises a therapeutically effective amount of MAPK blocker TRx0237 or pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers or auxiliary materials. The medicine composition for treating the alveolar echinococcosis based on the MAPK blocker TRx0237, provided by the invention, has remarkable advantages in multiple aspects, realizes precise targeted treatment on the echinococcosis multilocularis by specifically inhibiting a key pathogenic mechanism, namely an MAPK signal channel, not only can directly inhibit the growth of parasites, but also can effectively inhibit the echinococcosis multilocularis, so that the effect of treating the echinococcosis multilocularis is achieved. Liver tissue damage can be relieved, and the immune microenvironment of the liver can be improved.

The invention relates to the technical field of biological medicine, in particular to application of wogonin in preparation of a medicine for treating or inhibiting spinal cystic echinococcosis. The wogonin can accurately regulate and control the Nrf2-RTN4 signal axis and inhibit the generation of focus angiogenesis, so that the problem that the traditional medicine cannot block the key path Nrf2-RTN4-VEGF axis is solved, and the effect of treating or inhibiting the spinal cystic echinococcosis is achieved.

This invention provides an animal model of hepatic echinococcosis caused by *Echinococcus multilocularis*, its construction method, and its applications. The construction method mainly includes preserving the protoscolex, extracting the protoscolex of *Echinococcus multilocularis*, and injecting the preserved protoscolex into C57BL / 6N mice. The resulting mouse model can be used to observe the infection and development of hepatic echinococcosis, and to screen and / or evaluate hepatic echinococcosis drugs. The advantages of this invention are that it explores the growth pattern of *Echinococcus multilocularis* and its impact on the hepatic vascular system from a novel perspective. Furthermore, addressing the problems of complex and high-risk traditional modeling methods, it proposes an optimized liver-targeted inoculation pathway and establishes a standardized pathogen treatment process, ensuring infection success rate and animal survival rate while reducing experimental interference factors.

The present application relates to a kind of echinococcus Eg95 protein, nucleotide and mRNA for coding the protein of the present application.By optimizing echinococcus Eg95 protein amino acid and nucleotide sequence, echinococcus circular RNA vaccine, echinococcus linear mRNA vaccine and echinococcus self-replicating mRNA vaccine are prepared, the vaccine can provide strong immune protection to 4-month-old lambs only one needle immunization, so that it can still obtain more than 80% protection (higher than 70% required by Ministry of Agriculture and Rural Affairs) on the 180th day after immunization, solve the problem that commercial sheep echinococcosis genetic engineering subunit vaccine immunity is weak, and frequent vaccination is needed to obtain immune protection, reduce the repeated burden of vaccine procurement and labor cost, reduce the stress response to sheep flock, improve vaccination coverage and compliance, and be conducive to the prevention and control of our country hydatid disease.

The invention relates to the technical field of in-vitro diagnosis, and discloses an EB virus and echinococcosis antibody joint detection magnetic immunofluorescence detection micro-fluidic chip which comprises a chip body, the chip body is provided with a sample adding chamber, a liquid separation pool and a detection cavity which are communicated in sequence, and the chip body is further provided with a detergent chamber and a waste liquid pool; the detergent chamber is connected with the detection cavity through a washing valve; a hydrophobic modified layer is arranged on the surface of the inner wall of the washing valve; the opening rotating speed threshold value of the washing valve is higher than the centrifugal rotating speed for realizing plasma separation in the liquid separation pool; and one-step immunoreaction freeze-dried microspheres are preset in the detection cavity. According to the invention, a fluid control switch with a high opening threshold value for a liquid containing a surfactant is constructed by arranging a hydrophobic coating with a specific geometric size at the washing valve, so that the problem that the flow is out of control is solved, and the time sequence accuracy of a multi-step reaction is ensured.

The invention relates to the technical field of medical instruments, in particular to an X-ray guided minimally invasive interventional positioning puncture support for treating hepatic echinococcus granulosus. The X-ray guided minimally invasive interventional positioning puncture support comprises a fixed base, a turnover supporting arm, a transverse sliding platform, a height-adjustable mounting arm, a ball cup, a connecting arm, a positioner and a quick release mechanism. When the positioner needs to be detached from the puncture needle, only the servo motor needs to be started to drive the positive and negative tooth threaded rod to rotate, the two ball screw nut pairs are connected with the corresponding connecting pieces, so that the two arc-shaped sleeves are driven to move oppositely, after the two arc-shaped sleeves are separated from the puncture needle, the height-adjustable mounting arm is started, and the positioner can be detached from the puncture needle. Meanwhile, through the arrangement of a sliding rod, the structure of the two arc-shaped sleeves is more stable when the two arc-shaped sleeves are separated, displacement of the puncture needle is avoided, and then the influence on fine interventional therapy of the hepatic echinococcosis is avoided.

The application discloses a UP protein fragment and application thereof in human echinococcosis. The polypeptide comprises one or more of the amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9. The application further discloses application of the polypeptide or the marker combination in preparation of an antibody against echinococcosis or a diagnostic agent for diagnosing a disease caused by echinococcus granulosus. The new antigen UP of echinococcus in the application can be used to prepare an ELISA kit and used for clinical detection of human echinococcosis, and can be purified in a large amount, thereby facilitating large-scale screening of human echinococcosis.

This invention relates to the fields of biotechnology and parasite control technology, and proposes an enzyme that can promote the death of echinococcosis protocercariae in an acidic environment. This enzyme is a synthetic enzyme with the amino acid sequence SEQ ID NO:1. This invention achieves precise intervention in key links of echinococcosis transmission through synthetic enzyme technology, possessing high efficiency, safety, and feasibility, and has significant public health and veterinary application value.

The present application relates to the technical field of disease distribution prediction, and discloses a method and system for predicting the spatial distribution of alveolar echinococcosis based on multi-source environmental factors, comprising: obtaining multi-source environmental data of alveolar echinococcosis case points in a study area, processing the multi-source environmental data, and screening key environmental factors; obtaining a data set of sample points based on the key environmental factors, and dividing the data set into a training set and a test set; selecting a spatial prediction model, training and testing the spatial prediction model based on the training set and the test set, and obtaining an alveolar echinococcosis spatial prediction model; dividing the study area into a plurality of geographic units, obtaining the incidence probability of alveolar echinococcosis of each geographic unit based on the alveolar echinococcosis spatial prediction model, and determining the risk level. The present application can accurately predict the spatial distribution of alveolar echinococcosis by comprehensively considering multi-source environmental factors.